Expertise in
41
conditions

Dr. Sheetal Acharya

Hematology
Up Health System-Marquette | Cancer Center
850 W Baraga Ave, 
Marquette, MI 
Offers Telehealth
Expertise in
41
conditions
Up Health System-Marquette | Cancer Center
850 W Baraga Ave, 
Marquette, MI 

Overview

Sheetal Acharya is a Hematologist practicing medicine in Marquette, Michigan.

Dr. Acharya is highly rated in 41 conditions, according to our data. Her clinical expertise encompasses Adrenocortical Carcinoma, Testicular Cancer, Adrenal Cancer, Colorectal Cancer, and Orchiectomy.

She is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 12 clinical trials.

Specialties

Hematology

Licenses

Specialist in MI

Hospital Affiliations

Bell Hospital
Baraga County Memorial Hospital
Helen Newberry Joy Hospital
Uphs Marquette Dlp Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Up Health System-Marquette | Cancer Center
850 W Baraga Ave, Marquette, MI 49855

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2026
Intervention Type: Other
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
View 9 Less Clinical Trials

6 Total Publications

A Case of Three Synchronous Primary Lung Cancers of Distinct Histologies in a Patient With Severe Chronic Obstructive Pulmonary Disease.
A Case of Three Synchronous Primary Lung Cancers of Distinct Histologies in a Patient With Severe Chronic Obstructive Pulmonary Disease.
Journal: Cureus
Published: March 02, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Ross Siemers
Hematology | Oncology
Expertise in
19
conditions
Dr. Ross Siemers
Hematology | Oncology
Referral may be required

Marquette General Hospital

1414 W Fair Ave Ste 332, 
Marquette, MI 
 (0.1 miles away)
906-225-3922
Languages Spoken:
English
See accepted insurances

Ross Siemers is a Hematologist and an Oncologist practicing medicine in Marquette, Michigan. Dr. Siemers is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Myelogenous Leukemia (CML).

Expertise in
51
conditions
Dr. Anthony J. Jaslowski
Hematology | Oncology | Internal Medicine
Expertise in
51
conditions
Dr. Anthony J. Jaslowski
Hematology | Oncology | Internal Medicine
Referral may be required

OSF HealthCare Daniel J. Kobasic Cancer Clinic

3501 Ludington Street, 
Escanaba, MI 
 (56.4 miles away)
906-233-4140
Languages Spoken:
English
See accepted insurances

Anthony Jaslowski is a Hematologist and an Internal Medicine provider practicing medicine in Escanaba, Michigan. Dr. Jaslowski is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Colorectal Cancer, Bone Marrow Aspiration, and Myringotomy. Dr. Jaslowski is board certified in American Board Of Internal Medicine.

Expertise in
17
conditions
Dr. Edgard A. Badine
Hematology | Oncology | Internal Medicine
Expertise in
17
conditions
Dr. Edgard A. Badine
Hematology | Oncology | Internal Medicine
Referral may be required

OSF HealthCare Daniel J. Kobasic Cancer Clinic

3501 Ludington Street, 
Escanaba, MI 
 (56.4 miles away)
906-233-4140
Languages Spoken:
English, Arabic, French
See accepted insurances

Edgard Badine is a Hematologist and an Internal Medicine provider practicing medicine in Escanaba, Michigan. Dr. Badine is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Pancreatoblastoma, Pleuropulmonary Blastoma, Lung Cancer, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Badine is board certified in American Board Of Internal Medicine.

Frequently Asked Questions about Dr. Sheetal Acharya

How do I make an appointment with Dr. Sheetal Acharya?

You can book an appointment with Dr. Sheetal Acharya by calling their office at 906-449-3900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sheetal Acharya a top-rated expert for Adrenocortical Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sheetal Acharya is classified as an Distinguished expert for Adrenocortical Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sheetal Acharya specialize in?

While Dr. Sheetal Acharya is a Hematology, they have specific expertise in Adrenocortical Carcinoma, Testicular Cancer, and Adrenal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sheetal Acharya participate in research or clinical trials?

Yes. Dr. Sheetal Acharya has published 6 articles and abstracts on conditions like Adrenocortical Carcinoma. You can view a list of Dr. Sheetal Acharya's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sheetal Acharya accept my insurance?

Dr. Sheetal Acharya accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 906-449-3900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Acharya's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 32 Advanced Conditions
    View All 145 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile